Nul, a UK-based healthtech startup, has announced a $1 million seed funding round to support the development of its alcohol reduction platform, which integrates clinical care and prescription medication.

The Nul Platform

Nul's platform is based on a telehealth model that includes virtual consultations, ongoing clinical support, and structured digital guidance based on The Sinclair Method. The program utilizes naltrexone, a medication used to reduce alcohol cravings by targeting reward pathways.

Expansion and Growth

Nul launched a UK test phase in the summer of 2025, acquiring over 120 paying customers and reaching an annualised revenue run rate of over £300,000 within its first months. The seed funding will be used for the full UK commercial launch, expansion of its clinical and product teams, scaling of customer acquisition, and preparation for future international expansion, including the US market. The company also plans to launch a crowdfunding campaign on Republic Europe.